Reuters logo
BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin
November 1, 2017 / 1:06 PM / 23 days ago

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

Nov 1 (Reuters) - Mylan Nv

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

* Theravance Biopharma Inc - ‍remain on track to submit an NDA for Revefenacin Q4 of 2017​

* Theravance Biopharma Inc - ‍results demonstrated statistically significant and clinically meaningful improvements for revefenacin over placebo ​

* Theravance Biopharma Inc - ‍both doses of revefenacin had comparable rates of adverse events to placebo​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below